Navigation Links
Maxygen Announces Management Changes
Date:3/4/2008

roperty counsel for the company, reporting directly to the CEO. Dr. Kruse has been with Maxygen since March 1998. John Borkholder, who joined Maxygen in November 2005 as senior corporate counsel, has been promoted to chief corporate counsel and was appointed corporate secretary. Mr. Borkholder will continue to oversee the company's SEC and corporate governance compliance, and will take on an expanded corporate advisory role.

"I would like to acknowledge the significant contributions Michael Rabson has made to our company over the years," said Dr. Howard. "Under Michael's leadership, Maxygen has built an IP estate that is recognized as one of the best in the biotechnology industry(1) and a legal team with the expertise to grow and maintain the value of our products."

About Maxygen

Maxygen is a biopharmaceutical company focused on developing improved versions of protein drugs. The company's lead program, MAXY-G34, is designed to be an improved version of long-acting G-CSF for the treatment of neutropenia. MAXY-G34 is currently in Phase II clinical trials. Also in Maxygen's pipeline are a new Factor VIIa product candidate for the treatment of hemophilia and new CTLA4-Ig product candidates for the treatment of rheumatoid arthritis. Maxygen uses its proprietary DNA shuffling technology and extensive protein modification expertise to pursue the creation of biosuperior proteins. http://www.maxygen.com

(1) The Patent Scorecard(TM), http://www.patentboard.com


'/>"/>
SOURCE Maxygen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
2. Maxygen to Present at the Roth 20th Annual OC Growth Stock Conference
3. Maxygen to Present at the Stanford Group Company 13th Annual Healthcare Conference
4. Maxygen to Present at the JPMorgan 26th Annual Healthcare Conference
5. Maxygen Licenses Dengue Vaccine Technology to sanofi pasteur
6. Maxygen Reports Third Quarter 2007 Financial Results
7. Maxygen Announces Upcoming Webcasts at Investor Conferences
8. Maxygen Third Quarter 2007 Financial Results Conference Call Notice
9. Maxygen Announces Hold on MAXY-alpha Development Program
10. Nova Biosource Fuels Announces First Funding Under $41 Million Senior Secured Credit Facility
11. Exanet Announces ExaStore 2008 Clustered NAS System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... , July 29, 2014   Sequenom, Inc. ... company that provides innovative genetic analysis solutions, and ... esoteric laboratory services in the United States ... prenatal testing patents and applications. "We have ... and patient care, and we welcome the opportunity to ...
(Date:7/29/2014)... separated from its properties? On July 29, the prestigious ... the first Cheshire Cat experiment, separating a neutron from ... CA, and Vienna University of Technology. , Chesire Cat"Well! ... Alice in Wonderland, "but a grin without a cat! ... my life!" Alice,s surprise stems from her experience that ...
(Date:7/29/2014)... created a new way of manufacturing microstructured surfaces ... by self-assembly of carbon nanotubes, could exhibit a ... stiffness and strength, or the ability to repel ... demonstrated that mechanical forces can be used to ... that we can independently control the mechanical ...
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... 30 VEGA PROMOTIONAL SYSTEMS, INC. (Pink Sheets: VGPR) today ... Power Company, Inc. to assist the Company in building a ... Vega recently announced its intention to build a biomass plant ... materials in the State,s Bioenergy Corridor. Georgia ranks third ...
... Novavax, Inc. (Nasdaq: NVAX ) announced today ... (VLP) vaccine technology to ROVI Pharmaceuticals (Madrid: ROVI) of ... create a comprehensive influenza vaccine solution for the Spanish ... led by the Spanish Ministry of Health and other ...
... Bion Environmental Technologies, Inc. (OTC Bulletin Board: BNET) ... Patent application 11/592,513 entitled "Low Oxygen Biologically Mediated Nutrient ... on November 6, 2006; upon publication and issuance, the ... force until November 5, 2024. This new patent strengthens ...
Cached Biology Technology:Vega Picks Tennessee Firm to Assist with Construction of Biomass Plant in Georgia 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 2Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 3Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 4Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain 5Bion Announces Approval of New U.S. Patent that Broadens Protection for the Company's Livestock Waste Environmental Treatment Processes 2
(Date:7/29/2014)... wrong food at a restaurant, don,t blame yourself; blame the ... with what you want and more to do with a ... the selections of over 300 diners, the Cornell study published ... showed that when it comes to what you order ... the menu and how you imagine it will taste. , ...
(Date:7/29/2014)... debilitating effects of a stroke is an immensely ... as well as effective therapy. Advancing such knowledge ... the primary focus of research by Sergei Adamovich, ... the NJIT faculty more than a decade ago. ... substantial funding from sources such as the National ...
(Date:7/29/2014)... developed an easier method to create DNAprotein conjugates. ... in diagnosing diseases. , DNA linked to proteins ... that can be used in diagnostic techniques, nanotechnology ... proteins with DNA can be used for ... of biological material. The method also provides easier ...
Breaking Biology News(10 mins):Menu secrets that can make you slim by design 2Continuing the quest for better stroke therapies 2Continuing the quest for better stroke therapies 3New method provides researchers with efficient tool for tagging proteins 2
... February 20, 2012A team of researchers has found a ... will continue to be available, despite the potential attack ... Disease and poses a significant threat to the California ... Alamos National Laboratory (LANL), University of California at Davis ...
... PA, February 21, 2012 Using a noninvasive test on ... new algorithm for analysis, scientists can detect, with a high ... chromosomal abnormalities that cause Down syndrome and a genetic disorder ... scalable than other recently developed genetic screening tests and has ...
... has awarded The University of Texas at Austin and ... Dynamics Collaboratory (DDC), a network of researchers working to ... reliably predict the physical and ecological evolution of river ... the project, including Paola Passalacqua, assistant professor in Civil, ...
Cached Biology News:More grapes, less wrath: Hybrid antimicrobial protein protects grapevines from pathogen 2Noninvasive method accurately and efficiently detects risk of Down syndrome 2Noninvasive method accurately and efficiently detects risk of Down syndrome 3Engineering, geoscience faculty help lead $3 million NSF Delta research collaboration 2
... The HEEBO (Human Exonic Evidence Based ... Evidence Based Oligonucleotide ) Genome Set contain ... largely derived from constitutively expressed exons, allowing ... collaboration with leading researchers at Stanford University ...
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to FANCE ( Abpromise for all tested applications). entrezGeneID: 2178 SwissProtID: Q9HB96...
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Biology Products: